Based in Belgravia, the expansion of the private hospital operator’s clinical services will offer medical oncology and haematology care.
Private hospital Cleveland Clinic London is to construct an 81,000-square-foot cancer centre at 40 Grosvenor Place in Belgravia, London, to expand its cancer services. It will offer medical oncology and haematology care – including systemic cancer therapies, such as immunotherapy, chemotherapy, targeted therapies and radiotherapy.
In addition to cancer care, the clinic plans to introduce a wider range of clinical services at the facility in the future.
Construction is to begin in the fourth quarter of the year and it should be completed by the end of 2027.
“By expanding our services in London, we are addressing the growing demand for advanced cancer care and meeting the needs of patients closer to home,” said Cleveland Clinic chief executive Tom Mihaljevic.
International collaboration
According to Cancer Research UK, more than 375,000 new cancer cases are diagnosed every year in the UK and the rate is expected to rise as the population ages. The most common types of cancer diagnosed are breast, lung, prostate and colorectal cancer.
Consultants at Cleveland Clinic London will collaborate closely with colleagues at the group’s cancer programme in the United States and Abu Dhabi to bring multidisciplinary care, precision medicine, research, and cancer therapies to patients in the UK.
Cleveland Clinic London currently offers surgical treatment for a wide range of cancers, with a multidisciplinary team to personalise each patient’s care, as well as state-of-the-art imaging technology, including MRI, CT and ultrasound scanners. Current cancer-related offerings include treatment of adrenal, thyroid, head and neck, colorectal, liver, oesophageal, pancreatic, peritoneal, stomach, gynaecologic, lung, sarcoma, brain and spine tumours, and urologic cancers.
At the beginning of July, Bupa UK Insurance agreed a new multi-year contract with Cleveland Clinic in London. The agreement includes a first-of-its-kind value-based healthcare pilot and a no-shortfall guarantee for consultant fees.
